BioMerieux (CHIX:BIMP) Short-Term Debt : €0 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Short-Term Debt?

BioMerieux's Short-Term Debt for the quarter that ended in Dec. 2024 was €0 Mil.

BioMerieux's quarterly Short-Term Debt increased from Dec. 2023 (€136 Mil) to Jun. 2024 (€156 Mil) but then declined from Jun. 2024 (€156 Mil) to Dec. 2024 (€0 Mil).

BioMerieux's annual Short-Term Debt declined from Dec. 2022 (€161 Mil) to Dec. 2023 (€136 Mil) and declined from Dec. 2023 (€136 Mil) to Dec. 2024 (€0 Mil).

BioMerieux Short-Term Debt Historical Data

The historical data trend for BioMerieux's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Short-Term Debt Chart

BioMerieux Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

104.50

74.90

160.80

136.10

BioMerieux Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial															160.80	136.10	136.10	156.40	-

BioMerieux Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

BioMerieux Short-Term Debt Related Terms

Thank you for viewing the detailed overview of BioMerieux's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (CHIX:BIMp) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

BMXMF:USA 0RUG:UK BIM:France EYWN:Germany

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

BioMerieux Headlines

No Headlines